NYSE:NVO - Novo Nordisk A/S Stock Price, Forecast & News

Novo Nordisk A/S trades on the New York Stock Exchange (NYSE) under the ticker symbol "NVO."

Novo Nordisk A/S announced a Semi-Annual dividend on Friday, August 9th. Investors of record on Monday, August 19th will be given a dividend of $0.318 per share on Tuesday, August 27th. The ex-dividend date of this dividend is Friday, August 16th. View Novo Nordisk A/S's Dividend History.

Novo Nordisk A/S announced that its Board of Directors has authorized a share buyback program on Friday, February 2nd 2018, which permits the company to repurchase outstanding shares, according to EventVestor. This repurchase authorization permits the company to repurchase shares of its stock through open market purchases. Shares repurchase programs are generally an indication that the company's leadership believes its stock is undervalued.

Novo Nordisk A/S (NYSE:NVO) released its quarterly earnings data on Friday, November, 1st. The company reported $0.64 EPS for the quarter, beating the Thomson Reuters' consensus estimate of $0.62 by $0.02. The company earned $4.51 billion during the quarter, compared to the consensus estimate of $4.55 billion. Novo Nordisk A/S had a net margin of 32.44% and a return on equity of 75.48%. View Novo Nordisk A/S's Earnings History.

Novo Nordisk A/S is scheduled to release their next quarterly earnings announcement on Friday, February 7th 2020. View Earnings Estimates for Novo Nordisk A/S.

12 Wall Street analysts have issued 12 month target prices for Novo Nordisk A/S's stock. Their forecasts range from $48.61 to $400.00. On average, they expect Novo Nordisk A/S's share price to reach $181.58 in the next twelve months. This suggests a possible upside of 196.2% from the stock's current price. View Analyst Price Targets for Novo Nordisk A/S.

12 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Novo Nordisk A/S in the last year. There are currently 1 sell rating, 7 hold ratings and 4 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Novo Nordisk A/S.

News headlines about NVO stock have been trending very negative this week, according to InfoTrie Sentiment Analysis. The research firm identifies positive and negative press coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Novo Nordisk A/S earned a daily sentiment score of -3.8 on InfoTrie's scale. They also assigned media stories about the company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an effect on the stock's share price in the near term. View News Stories for Novo Nordisk A/S.

Some companies that are related to Novo Nordisk A/S include Johnson & Johnson (JNJ), Roche Holdings AG Basel (RHHBY), Merck & Co., Inc. (MRK), Pfizer (PFE), Novartis (NVS), Abbott Laboratories (ABT), Eli Lilly And Co (LLY), AstraZeneca (AZN), AbbVie (ABBV), Sanofi (SNY), GlaxoSmithKline (GSK), Bristol-Myers Squibb (BMY), Commonwealth Bank of Australia (CSLLY), Bayer (BAYRY) and Celgene (CELG).

Based on aggregate information from My MarketBeat watchlists, some companies that other Novo Nordisk A/S investors own include Gilead Sciences (GILD), AbbVie (ABBV), Pfizer (PFE), QUALCOMM (QCOM), Johnson & Johnson (JNJ), NVIDIA (NVDA), Starbucks (SBUX), AT&T (T), Cisco Systems (CSCO) and Alibaba Group (BABA).

Novo Nordisk A/S's stock is owned by a number of of institutional and retail investors. Top institutional shareholders include Scout Investments Inc. (0.01%), Atwater Malick LLC (0.00%), Commerzbank Aktiengesellschaft FI (0.00%), Smithbridge Asset Management Inc. DE (0.00%), OmniStar Financial Group Inc. (0.00%) and Clean Yield Group (0.00%). View Institutional Ownership Trends for Novo Nordisk A/S.

NVO stock was sold by a variety of institutional investors in the last quarter, including Commerzbank Aktiengesellschaft FI, First Hawaiian Bank, Scout Investments Inc., Smithbridge Asset Management Inc. DE, Norman Fields Gottscho Capital Management LLC, OmniStar Financial Group Inc., Gradient Investments LLC and Clean Yield Group. View Insider Buying and Selling for Novo Nordisk A/S.

NVO stock was bought by a variety of institutional investors in the last quarter, including Chemung Canal Trust Co., We Are One Seven LLC, Calamos Advisors LLC, Ingalls & Snyder LLC, Atwater Malick LLC, Huntington National Bank, Arlington Partners LLC and Boston Trust Walden Corp. View Insider Buying and Selling for Novo Nordisk A/S.

Shares of NVO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of NVO stock can currently be purchased for approximately $61.31.

Novo Nordisk A/S has a market capitalization of $145.18 billion and generates $17.72 billion in revenue each year. The company earns $5.91 billion in net income (profit) each year or $2.52 on an earnings per share basis. Novo Nordisk A/S employs 43,202 workers across the globe.View Additional Information About Novo Nordisk A/S.

The official website for Novo Nordisk A/S is http://www.novonordisk.com/.

Novo Nordisk A/S's mailing address is Novo Alle, Bagsvaerd G7, 2880. The company can be reached via phone at 45-4444-8888 or via email at [email protected]